{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:11:57Z","timestamp":1791267117855,"version":"4.1.0"},"publisher-location":"Cham","reference-count":108,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032231710","type":"print"},{"value":"9783032231727","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-23172-7_5","type":"book-chapter","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:10:13Z","timestamp":1777597813000},"page":"81-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Applications of Carbonic Anhydrase Inhibitors in Ophthalmology"],"prefix":"10.1007","author":[{"given":"Simone","family":"Giovannuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4103\/ijo.IJO_1917_20","volume":"69","author":"K Agarwal","year":"2021","unstructured":"Agarwal K, Vinekar A, Chandra P, Padhi TR, Nayak S, Jayanna S, Panchal B, Jalali S, Das T (2021) Imaging the pediatric retina: an overview. Indian J Ophthalmol 69:812\u2013823","journal-title":"Indian J Ophthalmol"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1021\/acs.jmedchem.3c02254","volume":"67","author":"A Angeli","year":"2024","unstructured":"Angeli A, Chelli I, Lucarini L, Sgambellone S, Marri S, Villano S, Ferraroni M, De Luca V, Capasso C, Carta F, Supuran CT (2024) Novel carbonic anhydrase inhibitors with dual-tail core sulfonamide show potent and lasting effects for glaucoma therapy. J Med Chem 67:3066\u20133089","journal-title":"J Med Chem"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/09273948.2022.2079532","volume":"31","author":"P Baquero-Ospina","year":"2023","unstructured":"Baquero-Ospina P, Paquent\u00edn-Jim\u00e9nez R, Hubbe-Tena C, Concha-Del-Rio LE (2023) Combined ophthalmology and rheumatology evaluation in systemic autoimmune diseases with ocular involvement: a third level reference Center in Mexico. Ocul Immunol Inflamm 31:989\u2013995","journal-title":"Ocul Immunol Inflamm"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.15171\/bi.2016.07","volume":"6","author":"J Barar","year":"2016","unstructured":"Barar J, Aghanejad A, Fathi M, Omidi Y (2016) Advanced drug delivery and targeting technologies for the ocular diseases. Bioimpacts 6:49\u201367","journal-title":"Bioimpacts"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0002-9394(54)92027-9","volume":"37","author":"B Becker","year":"1954","unstructured":"Becker B (1954) Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. Am J Ophthalmol 37:13\u201315","journal-title":"Am J Ophthalmol"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"7422","DOI":"10.1021\/acs.jmedchem.0c00733","volume":"63","author":"A Bonardi","year":"2020","unstructured":"Bonardi A, Nocentini A, Bua S, Combs J, Lomelino C, Andring J, Lucarini L, Sgambellone S, Masini E, McKenna R, Gratteri P, Supuran CT (2020) Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand\/isoform matching and selectivity of action. J Med Chem 63:7422\u20137444","journal-title":"J Med Chem"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/S0968-0896(99)00190-X","volume":"7","author":"J Borras","year":"1999","unstructured":"Borras J, Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT (1999) Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic\/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem 7:2397\u20132406","journal-title":"Bioorg Med Chem"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.2174\/0929867325666180622120625","volume":"26","author":"M Bozdag","year":"2019","unstructured":"Bozdag M, Altamimi ASA, Vullo D, Supuran CT, Carta F (2019) State of the art on carbonic anhydrase modulators for biomedical purposes. Curr Med Chem 26:2558\u20132573","journal-title":"Curr Med Chem"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.1016\/j.bmc.2015.07.047","volume":"23","author":"M Bragagni","year":"2015","unstructured":"Bragagni M, Bozdag M, Carta F, Scozzafava A, Lanzi C, Masini E, Mura P, Supuran CT (2015) Cyclodextrin complexation highly enhances efficacy of arylsulfonylureido benzenesulfonamide carbonic anhydrase inhibitors as a topical antiglaucoma agents. Bioorg Med Chem 23:6223\u20136227","journal-title":"Bioorg Med Chem"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, Ah Tong BAM, Arunga S, Bachani D, Bascaran C, Bastawrous A, Blanchet K, Braithwaite T, Buchan JC, Cairns J, Cama A, Chagunda M, Chuluunkhuu C, Cooper A, Crofts-Lawrence J, Dean WH, Denniston AK, Ehrlich JR, Emerson PM, Evans JR, Frick KD, Friedman DS, Furtado JM, Gichangi MM, Gichuhi S, Gilbert SS, Gurung R, Habtamu E, Holland P, Jonas JB, Keane PA, Keay L, Khanna RC, Khaw PT, Kuper H, Kyari F, Lansingh VC, Mactaggart I, Mafwiri MM, Mathenge W, McCormick I, Morjaria P, Mowatt L, Muirhead D, Murthy GVS, Mwangi N, Patel DB, Peto T, Qureshi BM, Salom\u00e3o SR, Sarah V, Shilio BR, Solomon AW, Swenor BK, Taylor HR, Wang N, Webson A, West SK, Wong TY, Wormald R, Yasmin S, Yusufu M, Silva JC, Resnikoff S, Ravilla T, Gilbert CE, Foster A, Faal HB (2021) The lancet global health commission on global eye health: vision beyond 2020. Lancet Glob Health 9:e489\u2013e551","journal-title":"Lancet Glob Health"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1021\/jm300031j","volume":"55","author":"F Carta","year":"2012","unstructured":"Carta F, Aggarwal M, Maresca A, Scozzafava A, McKenna R, Masini E, Supuran CT (2012) Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 55:1721\u20131730","journal-title":"J Med Chem"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1021\/jm400414j","volume":"56","author":"F Carta","year":"2013","unstructured":"Carta F, Akdemir A, Scozzafava A, Masini E, Supuran CT (2013) Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo. J Med Chem 56:4691\u20134700","journal-title":"J Med Chem"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1517\/13543776.2012.649006","volume":"22","author":"F Carta","year":"2012","unstructured":"Carta F, Supuran CT, Scozzafava A (2012) Novel therapies for glaucoma: a patent review 2007\u20132011. Expert Opin Ther Pat 22:79\u201388","journal-title":"Expert Opin Ther Pat"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41746-025-01954-y","volume":"8","author":"H Cheng","year":"2025","unstructured":"Cheng H, Wong JLY, Quek CWN, Goldberg JL, Mahajan VB, Wong TY, Mehta JS, Ting DSW, Ting DSJ (2025) Ophthalmic drug discovery and development using artificial intelligence and digital health technologies. NPJ Digit Med 8:573","journal-title":"NPJ Digit Med"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"10533","DOI":"10.1021\/acs.jmedchem.9b01033","volume":"63","author":"KJ Cheng","year":"2020","unstructured":"Cheng KJ, Hsieh CM, Nepali K, Liou JP (2020) Ocular disease therapeutics: design and delivery of drugs for diseases of the eye. J Med Chem 63:10533\u201310593","journal-title":"J Med Chem"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124\u2013136","journal-title":"Lancet"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ejmech.2018.04.002","volume":"151","author":"N Chiaramonte","year":"2018","unstructured":"Chiaramonte N, Bua S, Ferraroni M, Nocentini A, Bonardi A, Bartolucci G, Durante M, Lucarini L, Chiapponi D, Dei S, Manetti D, Teodori E, Gratteri P, Masini E, Supuran CT, Romanelli MN (2018) 2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem 151:363\u2013375","journal-title":"Eur J Med Chem"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","volume":"26","author":"P Csermely","year":"2005","unstructured":"Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26:178\u2013182","journal-title":"Trends Pharmacol Sci"},{"key":"5_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125507","volume":"674","author":"PHR Da Silva","year":"2025","unstructured":"Da Silva PHR, de Castro MA, Ribeiro MCS, Gon\u00e7alves LTA, de Melo LA, Freitas-Marques MB, Pedrosa TA, Pianetti GA, Fialho SL, Yoshida MI, da Nova Mussel W, Silva-Cunha A, Fernandes C (2025) Acetazolamide-loaded intravitreal implants for the treatment of glaucoma: formulation, physicochemical characterization and assessment of in vitro and in vivo safety. Int J Pharm 674:125507","journal-title":"Int J Pharm"},{"key":"5_CR20","first-page":"6424","volume":"26","author":"E Di Marco","year":"2022","unstructured":"Di Marco E, Aiello F, Lombardo M, Di Marino M, Missiroli F, Mancino R, Ricci F, Nucci C, Noce A, Di Daniele N, Cesareo M (2022) A literature review of hypertensive retinopathy: systemic correlations and new technologies. Eur Rev Med Pharmacol Sci 26:6424\u20136443","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.ijbiomac.2019.10.219","volume":"152","author":"V Dubey","year":"2020","unstructured":"Dubey V, Mohan P, Dangi JS, Kesavan K (2020) Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: formulation, characterization and pharmacodynamic study. Int J Biol Macromol 152:1224\u20131232","journal-title":"Int J Biol Macromol"},{"key":"5_CR22","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.935135","volume":"28","author":"J Dziedziak","year":"2022","unstructured":"Dziedziak J, Zaleska-\u017bmijewska A, Szaflik JP, Cudnoch-J\u0119drzejewska A (2022) Impact of arterial hypertension on the eye: a review of the pathogenesis, diagnostic methods, and treatment of hypertensive retinopathy. Med Sci Monit 28:e935135","journal-title":"Med Sci Monit"},{"key":"5_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123161","volume":"642","author":"NG Eissa","year":"2023","unstructured":"Eissa NG, Eldehna WM, Abdelazim EB, Eissa RA, Mohamed HH, Diab NH, El Hassab MA, Elkaeed EB, Elsayed ZM, Sabet MA, Bakr MH, Aboelela A, Abdelshafi NA, Kamoun EA, Supuran CT, Elsabahy M, Allam AA (2023) Morphologic design of nanogold carriers for a carbonic anhydrase inhibitor: effect on ocular retention and intraocular pressure. Int J Pharm 642:123161","journal-title":"Int J Pharm"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/jop.2011.0105","volume":"28","author":"MH Eren","year":"2012","unstructured":"Eren MH, Gungel H, Altan C, Pasaoglu IB, Sabanci S (2012) Comparison of dorzolamide\/timolol and latanoprost\/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma. J Ocul Pharmacol Ther 28:381\u2013386","journal-title":"J Ocul Pharmacol Ther"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bmc.2005.09.011","volume":"14","author":"LM Espinoza-Fonseca","year":"2006","unstructured":"Espinoza-Fonseca LM (2006) The benefits of the multi-target approach in drug design and discovery. Bioorg Med Chem 14:896\u2013897","journal-title":"Bioorg Med Chem"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/14756366.2011.597749","volume":"27","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi F, Mincione F, Somma T, Scozzafava G, Galassi F, Masini E, Impagnatiello F, Supuran CT (2012) A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 27:138\u2013147","journal-title":"J Enzyme Inhib Med Chem"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1021\/acs.jmedchem.9b02090","volume":"63","author":"M Fares","year":"2020","unstructured":"Fares M, Eldehna WM, Bua S, Lanzi C, Lucarini L, Masini E, Peat TS, Abdel-Aziz HA, Nocentini A, Keller PA, Supuran CT (2020) Discovery of potent dual-tailed benzenesulfonamide inhibitors of human carbonic anhydrases implicated in glaucoma and in vivo profiling of their intraocular pressure-lowering action. J Med Chem 63:3317\u20133326","journal-title":"J Med Chem"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/gels8080510","volume":"8","author":"AM Fea","year":"2022","unstructured":"Fea AM, Novarese C, Caselgrandi P, Boscia G (2022) Glaucoma treatment and hydrogel: current insights and state of the art. Gels 8:510","journal-title":"Gels"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1080\/10717544.2018.1477861","volume":"25","author":"NH Fouda","year":"2018","unstructured":"Fouda NH, Abdelrehim RT, Hegazy DA, Habib BA (2018) Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits. Drug Deliv 25:1340\u20131349","journal-title":"Drug Deliv"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/ceo.12905","volume":"45","author":"S Fraser-Bell","year":"2017","unstructured":"Fraser-Bell S, Symes R, Vaze A (2017) Hypertensive eye disease: a review. Clin Experiment Ophthalmol 45:45\u201353","journal-title":"Clin Experiment Ophthalmol"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1021\/acs.molpharmaceut.6b00343","volume":"13","author":"J Fu","year":"2016","unstructured":"Fu J, Sun F, Liu W, Liu Y, Gedam M, Hu Q, Fridley C, Quigley HA, Hanes J, Pitha I (2016) Subconjunctival delivery of Dorzolamide-loaded poly(ether-anhydride) microparticles produces sustained lowering of intraocular pressure in rabbits. Mol Pharm 13:2987\u20132995","journal-title":"Mol Pharm"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/archopht.1954.00920040745001","volume":"51","author":"WM Grant","year":"1954","unstructured":"Grant WM, Trotter RR (1954) Diamox (acetazolamide) in treatment of glaucoma. AMA Arch Ophthalmol 51:735\u2013739","journal-title":"AMA Arch Ophthalmol"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/jop.2013.0060","volume":"30","author":"BS Gudmundsdottir","year":"2014","unstructured":"Gudmundsdottir BS, Petursdottir D, Asgrimsdottir GM, Gottfredsdottir MS, Hardarson SH, J\u00f3hannesson G, Kurkov SV, Jansook P, Loftsson T, Stef\u00e1nsson E (2014) \u03b3-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man. J Ocul Pharmacol Ther 30:35\u201341","journal-title":"J Ocul Pharmacol Ther"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1034\/j.1600-0420.2001.079004336.x","volume":"79","author":"A Harris","year":"2001","unstructured":"Harris A, Jonescu-Cuypers C, Martin B, Kagemann L, Zalish M, Garzozi HJ (2001) Simultaneous management of blood flow and IOP in glaucoma. Acta Ophthalmol Scand 79:336\u2013341","journal-title":"Acta Ophthalmol Scand"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/IJN.S30725","volume":"8","author":"M Honda","year":"2013","unstructured":"Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N (2013) Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomed 8:495\u2013503","journal-title":"Int J Nanomed"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejpb.2010.07.005","volume":"76","author":"P Jansook","year":"2010","unstructured":"Jansook P, Stef\u00e1nsson E, Thorsteinsd\u00f3ttir M, Sigurdsson BB, Kristj\u00e1nsd\u00f3ttir SS, Bas JF, Sigurdsson HH, Loftsson T (2010) Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 76:208\u2013214","journal-title":"Eur J Pharm Biopharm"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0039-6257(95)80045-X","volume":"40","author":"JC Javitt","year":"1995","unstructured":"Javitt JC (1995) Preventing blindness in Americans: the need for eye health education. Surv Ophthalmol 40:41\u201344","journal-title":"Surv Ophthalmol"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/aos.12334","volume":"92","author":"G J\u00f3hannesson","year":"2014","unstructured":"J\u00f3hannesson G, Moya-Ortega MD, \u00c1sgr\u00edmsd\u00f3ttir GM, Lund SH, Thorsteinsd\u00f3ttir M, Loftsson T, Stef\u00e1nsson E (2014) Kinetics of \u03b3-cyclodextrin nanoparticle suspension eye drops in tear fluid. Acta Ophthalmol 92:550\u2013556","journal-title":"Acta Ophthalmol"},{"key":"5_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115086","volume":"27","author":"S Kalinin","year":"2019","unstructured":"Kalinin S, Valtari A, Ruponen M, Toropainen E, Kovalenko A, Nocentini A, Gureev M, Dar'in D, Urtti A, Supuran CT, Krasavin M (2019) Highly hydrophilic 1,3-oxazol-5-yl benzenesulfonamide inhibitors of carbonic anhydrase II for reduction of glaucoma-related intraocular pressure. Bioorg Med Chem 27:115086","journal-title":"Bioorg Med Chem"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.mcna.2021.01.004","volume":"105","author":"JM Kang","year":"2021","unstructured":"Kang JM, Tanna AP (2021) Glaucoma. Med Clin North Am 105:493\u2013510","journal-title":"Med Clin North Am"},{"key":"5_CR41","first-page":"205","volume":"15","author":"M Kouchak","year":"2016","unstructured":"Kouchak M, Bahmandar R, Bavarsad N, Farrahi F (2016) Ocular dorzolamide nanoliposomes for prolonged IOP reduction: in-vitroand in-vivo evaluation in rabbits. Iran J Pharm Res 15:205\u2013212","journal-title":"Iran J Pharm Res"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/03639045.2017.1386196","volume":"44","author":"M Kouchak","year":"2018","unstructured":"Kouchak M, Malekahmadi M, Bavarsad N, Saki Malehi A, Andishmand L (2018) Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Drug Dev Ind Pharm 44:1239\u20131242","journal-title":"Drug Dev Ind Pharm"},{"key":"5_CR43","volume":"16","author":"MJ Kumar Jr","year":"2024","unstructured":"Kumar MJ Jr, Kotak PS, Acharya S, Nelakuditi M, Parepalli A (2024) A comprehensive review of ocular manifestations in systemic diseases. Cureus 16:e65693","journal-title":"Cureus"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/10717544.2020.1731861","volume":"27","author":"T Li","year":"2020","unstructured":"Li T, Wang Y, Chen J, Gao X, Pan S, Su Y, Zhou X (2020) Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy. Drug Deliv 27:410\u2013421","journal-title":"Drug Deliv"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jdi.13480","volume":"12","author":"KY Lin","year":"2021","unstructured":"Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ (2021) Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig 12:1322\u20131325","journal-title":"J Diabetes Investig"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.bmcl.2012.12.058","volume":"23","author":"DD Long","year":"2013","unstructured":"Long DD, Frieman B, Hegde SS, Hill CM, Jiang L, Kintz S, Marquess DG, Purkey H, Shaw JP, Steinfeld T, Wilson MS, Wrench K (2013) A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist\/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 23:939\u2013943","journal-title":"Bioorg Med Chem Lett"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1755-3768.2011.02299.x","volume":"90","author":"T Loftsson","year":"2012","unstructured":"Loftsson T, Jansook P, Stef\u00e1nsson E (2012) Topical drug delivery to the eye: dorzolamide. Acta Ophthalmol 90:603\u2013608","journal-title":"Acta Ophthalmol"},{"key":"5_CR48","first-page":"277","volume":"2","author":"T Loftsson","year":"1996","unstructured":"Loftsson T, Stefansson E, Kristinsson JK, Fridriksdottir H, Sverrisson T, Gudmundsdottir G, Thorisdottir S (1996) Topically effective acetazolamide eye-drop solution in man. Pharm Pharmacol Commun 2:277\u2013279","journal-title":"Pharm Pharmacol Commun"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejpb.2012.06.015","volume":"82","author":"M Manconi","year":"2012","unstructured":"Manconi M, Caddeo C, Sinico C, Valenti D, Mostallino MC, Lampis S, Monduzzi M, Fadda AM (2012) Penetration enhancer-containing vesicles: composition dependence of structural features and skin penetration ability. Eur J Pharm Biopharm 82:352\u2013359","journal-title":"Eur J Pharm Biopharm"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","volume":"47","author":"TH Maren","year":"1967","unstructured":"Maren TH (1967) Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 47:595\u2013781","journal-title":"Physiol Rev"},{"key":"5_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1517\/13543776.2013.794788","volume":"23","author":"E Masini","year":"2013","unstructured":"Masini E, Carta F, Scozzafava A, Supuran CT (2013) Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 23:705\u2013716","journal-title":"Expert Opin Ther Pat"},{"key":"5_CR52","first-page":"269","volume-title":"Carbonic anhydrases, biochemistry and pharmacology of an evergreen pharmaceutical target","author":"E Masini","year":"2019","unstructured":"Masini E, Sgambellone S, Lucarini L (2019) Carbonic anhydrase inhibitors as ophthalmologic drugs for the treatment of glaucoma. In: Nocentini A, Supuran CT (eds) Carbonic anhydrases, biochemistry and pharmacology of an evergreen pharmaceutical target. Academic Press, pp 269\u2013285"},{"key":"5_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.109983","volume":"245","author":"R Maurya","year":"2024","unstructured":"Maurya R, Vikal A, Narang RK, Patel P, Kurmi BD (2024) Recent advancements and applications of ophthalmic gene therapy strategies: a breakthrough in ocular therapeutics. Exp Eye Res 245:109983","journal-title":"Exp Eye Res"},{"key":"5_CR54","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00590-019-02378-7","volume":"29","author":"AF Mavrogenis","year":"2019","unstructured":"Mavrogenis AF, Markatos K, Saranteas T, Ignatiadis I, Spyridonos S, Bumbasirevic M, Georgescu AV, Beris A, Soucacos PN (2019) The history of microsurgery. Eur J Orthop Surg Traumatol 29:247\u2013254","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"5_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3109\/14756369909030336","volume":"14","author":"L Menabuoni","year":"1999","unstructured":"Menabuoni L, Scozzafava A, Mincione F, Briganti F, Mincione G, Supuran CT (1999) Carbonic anhydrase inhibitors. Water-soluble, topically effective intraocular pressure lowering agents derived from isonicotinic acid and aromatic\/heterocyclic sulfonamides: is the tail more important than the ring? J Enzym Inhib 14:457\u2013474","journal-title":"J Enzym Inhib"},{"key":"5_CR56","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1021\/ja01167a012","volume":"72","author":"WH Miller","year":"1950","unstructured":"Miller WH, Dessert AM, Roblin RO Jr (1950) Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J Am Chem Soc 72:4893\u20134896","journal-title":"J Am Chem Soc"},{"key":"5_CR57","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1016\/j.bmcl.2011.04.046","volume":"21","author":"F Mincione","year":"2011","unstructured":"Mincione F, Benedini F, Biondi S, Cecchi A, Temperini C, Formicola G, Pacileo I, Scozzafava A, Masini E, Supuran CT (2011) Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 21:3216\u20133221","journal-title":"Bioorg Med Chem Lett"},{"key":"5_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0928-0987(99)00052-4","volume":"9","author":"G Mincione","year":"1999","unstructured":"Mincione G, Menabuoni L, Briganti F, Mincione F, Scozzafava A, Supuran CT (1999) Carbonic anhydrase inhibitors. Part 79. Synthesis of topically acting sulfonamides incorporating GABA moieties in their molecule, with long-lasting intraocular pressure-lowering properties. Eur J Pharm Sci 9:185\u2013199","journal-title":"Eur J Pharm Sci"},{"key":"5_CR59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.carbpol.2013.06.012","volume":"98","author":"MJ Mora","year":"2013","unstructured":"Mora MJ, T\u00e1rtara LI, Onnainty R, Palma SD, Longhi MR, Granero GE (2013) Characterization, dissolution and in vivo evaluation of solid acetazolamide complexes. Carbohydr Polym 98:380\u2013390","journal-title":"Carbohydr Polym"},{"key":"5_CR60","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejps.2017.04.013","volume":"104","author":"N Morsi","year":"2017","unstructured":"Morsi N, Ibrahim M, Refai H, El Sorogy H (2017) Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur J Pharm Sci 104:302\u2013314","journal-title":"Eur J Pharm Sci"},{"key":"5_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/10717544.2016.1233588","volume":"24","author":"SS Naguib","year":"2017","unstructured":"Naguib SS, Hathout RM, Mansour S (2017) Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug. Drug Deliv 24:99\u2013108","journal-title":"Drug Deliv"},{"key":"5_CR62","unstructured":"Nair S, Rui E (2007) Tricyclic inhibitors of carbonic anhydrase. WO0751482008"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1021\/acs.jmedchem.8b00625","volume":"61","author":"A Nocentini","year":"2018","unstructured":"Nocentini A, Ceruso M, Bua S, Lomelino CL, Andring JT, McKenna R, Lanzi C, Sgambellone S, Pecori R, Matucci R, Filippi L, Gratteri P, Carta F, Masini E, Selleri S, Supuran CT (2018) Discovery of \u03b2-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy. J Med Chem 61:5380\u20135394","journal-title":"J Med Chem"},{"key":"5_CR64","doi-asserted-by":"publisher","first-page":"10692","DOI":"10.1021\/acs.jmedchem.6b01389","volume":"59","author":"A Nocentini","year":"2016","unstructured":"Nocentini A, Ferraroni M, Carta F, Ceruso M, Gratteri P, Lanzi C, Masini E, Supuran CT (2016) Benzenesulfonamides incorporating flexible Triazole moieties are highly effective carbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations. J Med Chem 59:10692\u201310704","journal-title":"J Med Chem"},{"key":"5_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.02.035","volume":"522","author":"CG Park","year":"2017","unstructured":"Park CG, Kim YK, Kim SN, Lee SH, Huh BK, Park MA, Won H, Park KH, Choy YB (2017) Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles. Int J Pharm 522:66\u201373","journal-title":"Int J Pharm"},{"key":"5_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/tvst.7.2.13","volume":"7","author":"I Pitha","year":"2018","unstructured":"Pitha I, Kimball EC, Oglesby EN, Pease ME, Fu J, Schaub J, Kim YC, Hu Q, Hanes J, Quigley HA (2018) Sustained Dorzolamide release prevents axonal and retinal ganglion cell loss in a rat model of IOP-glaucoma. Transl Vis Sci Technol 7:13","journal-title":"Transl Vis Sci Technol"},{"key":"5_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cge.12389","volume":"86","author":"LF Porter","year":"2014","unstructured":"Porter LF, Black GC (2014) Personalized ophthalmology. Clin Genet 86:1\u201311","journal-title":"Clin Genet"},{"key":"5_CR68","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","volume":"377","author":"HA Quigley","year":"2011","unstructured":"Quigley HA (2011) Glaucoma. Lancet 377:1367\u20131377","journal-title":"Lancet"},{"key":"5_CR69","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:262\u2013267","journal-title":"Br J Ophthalmol"},{"key":"5_CR70","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/eye.1993.159","volume":"7","author":"SM Rassam","year":"1993","unstructured":"Rassam SM, Patel V, Kohner EM (1993) The effect of acetazolamide on the retinal circulation. Eye 7:697\u2013702","journal-title":"Eye"},{"key":"5_CR71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/1120672119893291","volume":"30","author":"HW Roberts","year":"2020","unstructured":"Roberts HW, Day AC, O'Brart DP (2020) Femtosecond laser-assisted cataract surgery: a review. Eur J Ophthalmol 30:417\u2013429","journal-title":"Eur J Ophthalmol"},{"key":"5_CR72","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.addr.2019.10.006","volume":"148","author":"FF Sahle","year":"2019","unstructured":"Sahle FF, Kim S, Niloy KK, Tahia F, Fili CV, Cooper E, Hamilton DJ, Lowe TL (2019) Nanotechnology in regenerative ophthalmology. Adv Drug Deliv Rev 148:290\u2013307","journal-title":"Adv Drug Deliv Rev"},{"key":"5_CR73","unstructured":"Schoen U, Waldeck H, Reinecker U, Peter-Colin G, Dania R, Holger S, Michael W, Jochen A (2010) Novel sulfamate compounds for medical use. WO0502522009"},{"key":"5_CR74","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1021\/jm9901879","volume":"42","author":"A Scozzafava","year":"1999","unstructured":"Scozzafava A, Briganti F, Mincione G, Menabuoni L, Mincione F, Supuran CT (1999) Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl\/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem 42:3690\u20133700","journal-title":"J Med Chem"},{"key":"5_CR75","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1021\/jm9900523","volume":"42","author":"A Scozzafava","year":"1999","unstructured":"Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT (1999) Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic\/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 42:2641\u20132650","journal-title":"J Med Chem"},{"key":"5_CR76","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1021\/jm000296j","volume":"43","author":"A Scozzafava","year":"2000","unstructured":"Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT (2000) Carbonic anhydrase inhibitors: perfluoroalkyl\/aryl-substituted derivatives of aromatic\/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J Med Chem 43:4542\u20134551","journal-title":"J Med Chem"},{"key":"5_CR77","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-94-007-7359-2_17","volume":"75","author":"A Scozzafava","year":"2014","unstructured":"Scozzafava A, Supuran CT (2014) Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem 75:349\u2013359","journal-title":"Subcell Biochem"},{"key":"5_CR78","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/10837450.2021.1944206","volume":"26","author":"PI Siafaka","year":"2021","unstructured":"Siafaka PI, \u00c7a\u011flar E\u015e, Sipahi H, Charehsaz M, Ayd\u0131n A, \u00dcst\u00fcnda\u011f Okur N (2021) Ocular microemulsion of brinzolamide: formulation, physicochemical characterization, and in vitro irritation studies based on EpiOcular\u2122 eye irritation assay. Pharm Dev Technol 26:765\u2013778","journal-title":"Pharm Dev Technol"},{"key":"5_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.survophthal.2008.06.002","volume":"54","author":"B Siesky","year":"2009","unstructured":"Siesky B, Harris A, Brizendine E, Marques C, Loh J, Mackey J, Overton J, Netland P (2009) Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol 54:33\u201346","journal-title":"Surv Ophthalmol"},{"key":"5_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jconrel.2004.10.004","volume":"102","author":"HH Sigurdsson","year":"2005","unstructured":"Sigurdsson HH, Stef\u00e1nsson E, Gudmundsd\u00f3ttir E, Eysteinsson T, Thorsteinsd\u00f3ttir M, Loftsson T (2005) Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Release 102:255\u2013262","journal-title":"J Control Release"},{"key":"5_CR81","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3109\/03639045.2013.814061","volume":"40","author":"J Singh","year":"2014","unstructured":"Singh J, Chhabra G, Pathak K (2014) Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. Ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm 40:1223\u20131223","journal-title":"Drug Dev Ind Pharm"},{"key":"5_CR82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","volume":"21","author":"RJ Slack","year":"2022","unstructured":"Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD (2022) Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov 21:60\u201378","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR83","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1016\/j.bmcl.2009.10.036","volume":"19","author":"RM Steele","year":"2009","unstructured":"Steele RM, Benedini F, Biondi S, Borghi V, Carzaniga L, Impagnatiello F, Miglietta D, Chong WK, Rajapakse R, Cecchi A, Temperini C, Supuran CT (2009) Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 19:6565\u20136570","journal-title":"Bioorg Med Chem Lett"},{"key":"5_CR84","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1136\/bjophthalmol-2021-319530","volume":"106","author":"A Stoner","year":"2022","unstructured":"Stoner A, Harris A, Oddone F, Belamkar A, Verticchio Vercellin AC, Shin J, Januleviciene I, Siesky B (2022) Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Br J Ophthalmol 106:1332\u20131337","journal-title":"Br J Ophthalmol"},{"key":"5_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.733080","volume":"8","author":"L Storgaard","year":"2021","unstructured":"Storgaard L, Tran TL, Freiberg JC, Hauser AS, Kolko M (2021) Glaucoma clinical research: trends in treatment strategies and drug development. Front Med (Lausanne) 8:733080","journal-title":"Front Med (Lausanne)"},{"key":"5_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1350-9462(99)00006-3","volume":"19","author":"MF Sugrue","year":"2000","unstructured":"Sugrue MF (2000) Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 19:87\u2013112","journal-title":"Prog Retin Eye Res"},{"key":"5_CR87","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/DDDT.S153405","volume":"12","author":"J Sun","year":"2018","unstructured":"Sun J, Zhou Z (2018) A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation. Drug Des Devel Ther 12:383\u2013389","journal-title":"Drug Des Devel Ther"},{"key":"5_CR88","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.4155\/fmc.11.69","volume":"3","author":"CT Supuran","year":"2011","unstructured":"Supuran CT (2011) Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 3:1165\u20131180","journal-title":"Future Med Chem"},{"key":"5_CR89","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/13543776.2019.1679117","volume":"29","author":"CT Supuran","year":"2019","unstructured":"Supuran CT, Altamimi ASA, Carta F (2019) Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013\u20132019. Expert Opin Ther Pat 29:781\u2013792","journal-title":"Expert Opin Ther Pat"},{"key":"5_CR90","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0928-0987(99)00022-6","volume":"8","author":"CT Supuran","year":"1999","unstructured":"Supuran CT, Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G (1999) Carbonic anhydrase inhibitors. Part 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties. Eur J Pharm Sci 8:317\u2013328","journal-title":"Eur J Pharm Sci"},{"key":"5_CR91","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1021\/acs.jmedchem.3c02279","volume":"67","author":"HO Tawfik","year":"2024","unstructured":"Tawfik HO, Saleh MM, Ammara A, Khaleel EF, Badi R, Khater YTT, Rasheed RA, Attia AA, Hefny SM, Elkaeed EB, Nocentini A, Supuran CT, Eldehna WM, Shaldam MA (2024) Discovery of novel pyridazine-tethered sulfonamides as carbonic anhydrase II inhibitors for the management of glaucoma. J Med Chem 67:1611\u20131623","journal-title":"J Med Chem"},{"key":"5_CR92","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaapos.2019.03.003","volume":"23","author":"LK To","year":"2019","unstructured":"To LK, Shah PR, Scanga HL, Franks AL, Cladis FP, Nischal KK (2019) Personalized pediatric ophthalmology: a case report. J AAPOS 23:234\u2013236","journal-title":"J AAPOS"},{"key":"5_CR93","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/10717544.2013.834417","volume":"20","author":"P Verma","year":"2013","unstructured":"Verma P, Gupta RN, Jha AK, Pandey R (2013) Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide. Drug Deliv 20:269\u2013276","journal-title":"Drug Deliv"},{"key":"5_CR94","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000453527","volume":"57","author":"A Vicente","year":"2017","unstructured":"Vicente A, Prudhomme S, Ferreira J, Abeg\u00e3o Pinto L, Stalmans I (2017) Open-angle glaucoma: drug development pipeline during the last 20 years (1995\u20132015). Ophthalmic Res 57:201\u2013207","journal-title":"Ophthalmic Res"},{"key":"5_CR95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/ICU.0b013e328332f562","volume":"21","author":"G Vizzeri","year":"2010","unstructured":"Vizzeri G, Weinreb RN (2010) Cataract surgery and glaucoma. Curr Opin Ophthalmol 21:20\u201324","journal-title":"Curr Opin Ophthalmol"},{"key":"5_CR96","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1021\/acs.jmedchem.6b00462","volume":"59","author":"D Vullo","year":"2016","unstructured":"Vullo D, Durante M, Di Leva FS, Cosconati S, Masini E, Scozzafava A, Novellino E, Supuran CT, Carta F (2016) Monothiocarbamates strongly inhibit carbonic anhydrases in vitro and possess intraocular pressure lowering activity in an animal model of glaucoma. J Med Chem 59:5857\u20135867","journal-title":"J Med Chem"},{"key":"5_CR97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fphar.2018.00091","volume":"9","author":"F Wang","year":"2018","unstructured":"Wang F, Bao X, Fang A, Li H, Zhou Y, Liu Y, Jiang C, Wu J, Song X (2018) Nanoliposome-encapsulated brinzolamide-hydropropyl-\u03b2-cyclodextrin inclusion complex: a potential therapeutic ocular drug-delivery system. Front Pharmacol 9:91","journal-title":"Front Pharmacol"},{"key":"5_CR98","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3109\/1061186X.2014.939983","volume":"22","author":"F Wang","year":"2014","unstructured":"Wang F, Chen L, Zhang D, Jiang S, Shi K, Huang Y, Li R, Xu Q (2014) Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target 22:849\u2013858","journal-title":"J Drug Target"},{"key":"5_CR99","first-page":"279","volume":"4","author":"S Wolf","year":"1995","unstructured":"Wolf S, Arend O, Haase A (1995) Retinal hemodynamics in patients with chronic open-angle glaucoma. Ger J Ophthalmol 4:279\u2013282","journal-title":"Ger J Ophthalmol"},{"key":"5_CR100","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13346-014-0196-9","volume":"4","author":"TT Wong","year":"2014","unstructured":"Wong TT, Novack GD, Natarajan JV, Ho CL, Htoon HM, Venkatraman SS (2014) Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res 4:303\u2013309","journal-title":"Drug Deliv Transl Res"},{"key":"5_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121012","volume":"607","author":"KB Wr\u00f3blewska","year":"2021","unstructured":"Wr\u00f3blewska KB, Jadach B, Muszalska-Kolos I (2021) Progress in drug formulation design and delivery of medicinal substances used in ophthalmology. Int J Pharm 607:121012","journal-title":"Int J Pharm"},{"key":"5_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229682","volume":"15","author":"Y Xing","year":"2020","unstructured":"Xing Y, Zhu L, Zhang K, Huang S (2020) The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: a systematic review and meta-analysis. PLoS One 15:e0229682","journal-title":"PLoS One"},{"key":"5_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105887","volume":"163","author":"J Youshia","year":"2021","unstructured":"Youshia J, Kamel AO, El Shamy A, Mansour S (2021) Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs. Eur J Pharm Sci 163:105887","journal-title":"Eur J Pharm Sci"},{"key":"5_CR104","doi-asserted-by":"publisher","first-page":"1325868","DOI":"10.3389\/fimmu.2024.1325868","volume":"15","author":"W Yuan","year":"2024","unstructured":"Yuan W, Li X, Wang G, Qu B, Zhao F (2024) Association of autoimmune and allergic diseases with senile cataract: a bidirectional two-sample Mendelian randomization study. Front Immunol 15:1325868","journal-title":"Front Immunol"},{"key":"5_CR105","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/medicina59122114","volume":"59","author":"M Zeppieri","year":"2023","unstructured":"Zeppieri M, Marsili S, Enaholo ES, Shuaibu AO, Uwagboe N, Salati C, Spadea L, Musa M (2023) Optical coherence tomography (OCT): a brief look at the uses and technological evolution of ophthalmology. Medicina (Kaunas) 59:2114","journal-title":"Medicina (Kaunas)"},{"key":"5_CR106","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrd3745","volume":"11","author":"K Zhang","year":"2012","unstructured":"Zhang K, Zhang L, Weinreb RN (2012) Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 11:541\u2013559","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR107","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.carbpol.2013.06.052","volume":"98","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Ren K, He Z, Li H, Chen T, Lei Y, Xia S, He G, Xie Y, Zheng Y, Song X (2013) Development of inclusion complex of brinzolamide with hydroxypropyl-\u03b2-cyclodextrin. Carbohydr Polym 98:638\u2013643","journal-title":"Carbohydr Polym"},{"key":"5_CR108","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nature14650","volume":"523","author":"L Zhao","year":"2015","unstructured":"Zhao L, Chen XJ, Zhu J, Xi YB, Yang X, Hu LD, Ouyang H, Patel SH, Jin X, Lin D, Wu F, Flagg K, Cai H, Li G, Cao G, Lin Y, Chen D, Wen C, Chung C, Wang Y, Qiu A, Yeh E, Wang W, Hu X, Grob S, Abagyan R, Su Z, Tjondro HC, Zhao XJ, Luo H, Hou R, Jefferson J, Perry P, Gao W, Kozak I, Granet D, Li Y, Sun X, Wang J, Zhang L, Liu Y, Yan YB, Zhang K (2015) Lanosterol reverses protein aggregation in cataracts. Nature 523:607\u2013611","journal-title":"Nature"}],"container-title":["Subcellular Biochemistry","Carbonic Anhydrase Inhibitors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-23172-7_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:10:16Z","timestamp":1777597816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-23172-7_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032231710","9783032231727"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-23172-7_5","relation":{},"ISSN":["0306-0225","2542-8810"],"issn-type":[{"value":"0306-0225","type":"print"},{"value":"2542-8810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}